Fetch Pharma is a life science company developing homologues of human biotech drugs for America's 75 million pet dogs. Biologics are among the top-selling drugs for humans yet there are no marketed canine-specific biologics. Fetch intends to change that by developing a portfolio of products for intractable canine diseases such as cancer, anemia and arthritis. The company expects to be cash flow positive in 5 years based on sales of 2 products.